Trial Profile
A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Skin cancer
- Focus Biomarker; Therapeutic Use
- 11 Apr 2013 New trial record